How to buy Vivos Therapeutics stock - 17 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vivos Therapeutics stock

Own Vivos Therapeutics stock in just a few minutes.

Vivos Therapeutics, Inc is a medical devices business based in the US. Vivos Therapeutics shares (VVOS) are listed on the NASDAQ and all prices are listed in US Dollars. Vivos Therapeutics employs 93 staff and has a trailing 12-month revenue of around USD$13.1 million.

How to buy shares in Vivos Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Vivos Therapeutics. Find the stock by name or ticker symbol: VVOS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vivos Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Vivos Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Vivos Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Vivos Therapeutics share price

Use our graph to track the performance of VVOS stocks over time.

Vivos Therapeutics shares at a glance

Information last updated 2021-04-16.
52-week rangeUSD$5.64 - USD$14.41
50-day moving average USD$7.5977
200-day moving average USD$7.3874
Wall St. target priceUSD$12
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Vivos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vivos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vivos Therapeutics financials

Revenue TTM USD$13.1 million
Gross profit TTM USD$10.4 million
Return on assets TTM -33.11%
Return on equity TTM -157.7%
Profit margin -92.28%
Book value N/A
Market capitalisation USD$152.1 million

TTM: trailing 12 months

Shorting Vivos Therapeutics shares

There are currently 41,931 Vivos Therapeutics shares held short by investors – that's known as Vivos Therapeutics's "short interest". This figure is 166.3% up from 15,747 last month.

There are a few different ways that this level of interest in shorting Vivos Therapeutics shares can be evaluated.

Vivos Therapeutics's "short interest ratio" (SIR)

Vivos Therapeutics's "short interest ratio" (SIR) is the quantity of Vivos Therapeutics shares currently shorted divided by the average quantity of Vivos Therapeutics shares traded daily (recently around 97513.953488372). Vivos Therapeutics's SIR currently stands at 0.43. In other words for every 100,000 Vivos Therapeutics shares traded daily on the market, roughly 430 shares are currently held short.

To gain some more context, you can compare Vivos Therapeutics's short interest ratio against those of similar companies.

However Vivos Therapeutics's short interest can also be evaluated against the total number of Vivos Therapeutics shares, or, against the total number of tradable Vivos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vivos Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Vivos Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0032% of the tradable shares (for every 100,000 tradable Vivos Therapeutics shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vivos Therapeutics.

Find out more about how you can short Vivos Therapeutics stock.

Vivos Therapeutics share dividends

We're not expecting Vivos Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Vivos Therapeutics overview

Vivos Therapeutics, Inc. , a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site